All In Biotech

Drug Trial Radar · NCT00082433

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane

Last checked: Nov 20, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,221 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,221

Actual

Start

Nov 2003

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Lead sponsor
R-PharmIndustry
Sponsor type
Industry
First posted
May 11, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.

Conditions

  • Cancer
  • Breast Cancer

Interventions

  • Ixabepilone + CapecitabineDrug

    Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle

  • CapecitabineDrug

    Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: from date of randomization until death

Locations

186 sites in 29 countries. Site status is shown where the registry gives one.

  • Local Institution

    Tucson, Arizona

  • Local Institution

    Beverly Hills, California

  • Local Institution

    Corona, California

  • Local Institution

    Hartford, Connecticut

  • Local Institution

    Plantation, Florida

  • Local Institution

    Boise, Idaho

  • Local Institution

    Evanston, Illinois

  • Local Institution

    Iowa City, Iowa

  • Local Institution

    Louisville, Kentucky

  • Local Institution

    Baton Rouge, Louisiana

  • Local Institution

    Bethesda, Maryland

  • Local Institution

    Boston, Massachusetts

  • Local Institution

    Jackson, Mississippi

  • Local Institution

    Columbia, Missouri

  • Local Institution

    Voorhees Township, New Jersey

  • Local Institution

    Albuquerque, New Mexico

  • Local Institution

    Latham, New York

  • Local Institution

    Mineola, New York

  • Local Institution

    New York, New York

  • Local Institution

    The Bronx, New York

  • Local Institution

    Durham, North Carolina

  • Local Institution

    Goldsboro, North Carolina

  • Local Institution

    Hickory, North Carolina

  • Local Institution

    Kinston, North Carolina

  • Local Institution

    Canton, Ohio

  • Local Institution

    Columbus, Ohio

  • Local Institution

    Langhorne, Pennsylvania

  • Local Institution

    Knoxville, Tennessee

  • Local Institution

    Memphis, Tennessee

  • Local Institution

    Dallas, Texas

  • Local Institution

    Charlottesville, Virginia

  • Local Institution

    Norfolk, Virginia

  • Local Institution

    Richmond, Virginia

  • Local Institution

    Marshfield, Wisconsin

  • Local Institution

    Buenos Aires, Argentina

  • Local Institution

    Mendoza, Argentina

  • Local Institution

    Salta, Argentina

  • Local Institution

    Santa Fe, Argentina

  • Local Institution

    Avellaneda, Buenos Aires, Argentina

  • Local Institution

    Bahía Blanca, Buenos Aires, Argentina

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.